期刊
MEDICAL JOURNAL OF AUSTRALIA
卷 212, 期 6, 页码 279-+出版社
WILEY
DOI: 10.5694/mja2.50355
关键词
Bacterial infections; Infection control
资金
- Australian National Health and Medical Research Council [1104232, 1107322]
- AmpliPhi Biosciences Corporation
- National Health and Medical Research Council of Australia [1104232, 1107322] Funding Source: NHMRC
Bacteriophage (phage) therapy is re-emerging a century after it began. Activity against antibiotic-resistant pathogens and a lack of serious side effects make phage therapy an attractive treatment option in refractory bacterial infections. Phages are highly specific for their bacterial targets, but the relationship between in vitro activity and in vivo efficacy remains to be rigorously evaluated. Pharmacokinetic and pharmacodynamic principles of phage therapy are generally based on the classic predator-prey relationship, but numerous other factors contribute to phage clearance and optimal dosing strategies remain unclear. Combinations of fully characterised, exclusively lytic phages prepared under good manufacturing practice are limited in their availability. Safety has been demonstrated but randomised controlled trials are needed to evaluate efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据